12th November 2016
Costly methods of diagnosis such as the SPECT scan or the PET scan are used for the
indication of Parkinson's Disease. However, in early Parkinson's Disease a far less costly and
relatively non-invasive biomarker would be preferable.
Researchers have identified a peptoid called PD2, which significantly
binds higher levels of IgG3 antibody in those people with Parkinson's
Disease. The PD2 peptoid was found to be 68% accurate in
identifying Parkinson's Disease, which is less accurate than existing
methods.
However, PD2 was 84% accurate in identifying new cases
of Parkinson's Disease. It is new cases of Parkinson's Disease that
existing methods are not so accurate with. PD2 levels are also
positively correlated with the United Parkinson's Disease Rating Scale
score, which is the primary symptom questionnaire for Parkinson's
Disease. So the researchers concluded that PD2 may be useful for the
diagnosis of early Parkinson's Disease.
Reference : NPJ Parkinsons Disease [2016] 16012 Epub Jun 23 (U.Yazdani, S.Zaman,
L.S.Hynan, L.S.Brown, R.B.Dewey, D.Karp, D.C.German)
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/27812535
http://www.viartis.net/parkinsons.disease/news/161112.pdf
mail@viartis.net
No comments:
Post a Comment